GlassScriptPhysician profile
Eduardo A Herrera
NPI 1750474052
$1,192.55
in general payments reported to CMS, 2019-2025
28 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $216 · 2021: $242 · 2022: $191 · 2023: $162 · 2024: $98.61 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.64 | 2019-2022 | |
| Myriad Women'S Health, INC. | $79.52 | 2023 | Myrisk |
| Organon LLC | $71.35 | 2021-2025 | Nexplanon |
| Aspira Women'S Health INC | $54.57 | 2021 | |
| Roche Diagnostics Corporation | $52.78 | 2019-2020 | |
| Dexcom, INC. | $51.83 | 2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $50.36 | 2024 | Slynd |
| Merck Sharp & Dohme LLC | $46.95 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $45.55 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $44.12 | 2020-2025 | |
| Astellas Pharma US INC | $43.03 | 2020-2023 | Veozah |
| Becton, Dickinson and Company | $38.22 | 2022 | |
| Millicent US INC | $37.24 | 2019-2025 | Femlyv, Intrarosa |
| Urovant Sciences INC | $36.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.15 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $31.20 | 2024 | Hemoblast Bellows |
| Pfizer INC. | $21.00 | 2022 | |
| Scynexis, INC. | $17.66 | 2022 | |
| Smith+Nephew, INC. | $16.79 | 2025 | Pico 14 |
| Duchesnay USA Incorporated | $15.97 | 2020 | |
| Therapeuticsmd, INC. | $14.76 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.50 | 2025 | |
| Minerva Surgical, INC | $14.13 | 2020 | |
| Renovia INC | $11.61 | 2021 | |
| Coopersurgical, INC. | $11.50 | 2021 | |
| Lupin INC. | $11.43 | 2020 | |
| Meditrina | $11.05 | 2025 | |
| Evofem Biosciences, INC. | $6.27 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.